<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
71863-210-06
</NDCCode>
<PackageDescription>
10 AMPULE in 1 CARTON (71863-210-06) > 5 mL in 1 AMPULE (71863-210-05)
</PackageDescription>
<NDC11Code>
71863-0210-06
</NDC11Code>
<ProductNDC>
71863-210
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Rezipres
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Ephedrine Hydrochloride
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName>
INTRAVENOUS
</RouteName>
<StartMarketingDate>
20210614
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA213536
</ApplicationNumber>
<LabelerName>
Eton Pharmaceuticals, Inc.
</LabelerName>
<SubstanceName>
EPHEDRINE HYDROCHLORIDE
</SubstanceName>
<StrengthNumber>
4.7
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes>
alpha-Adrenergic Agonist [EPC],Adrenergic alpha-Agonists [MoA],beta-Adrenergic Agonist [EPC],Adrenergic beta-Agonists [MoA],Norepinephrine Releasing Agent [EPC],Increased Norepinephrine Activity [PE]
</Pharm_Classes>
<DEASchedule/>
<Status>
Deprecated
</Status>
<LastUpdate>
2021-10-06
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20221231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20211001
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>